Глава 14. Саркоидоз

Черников А.Ю. Об эффективности медицинской реабилитации больных саркоидозом в общей лечебной сети // Здравоохранение Российской Федерации. 2008. № 4. С. 36–39.

Шмелев Е.И. Дифференциальная диагностика диссеминированных заболеваний легких неопухолевой природы // РМЖ. 2001. № 21. С. 918–922.

Шмелев Е.И. Саркоидоз // Атмосфера. Пульмонология и аллергология. 2004. № 2 (13). С. 3–10.

Adami G., Saag K.G. Glucocorticoid-induced osteoporosis: 2019 concise clinical review // Osteoporos. Int. 2019. Vol. 30. N. 6. P. 1145–1156. DOI: https://doi.org/10.1007/s00198-019-04906-x.

Antonovich D.D., Callen J.P. Development of sarcoidosis in cosmetic tattoos // Arch. Dermatol. 2005. Vol. 141. N. 7. P. 869–872.

ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders // Eur. Respir. J. 1999. Vol. 14. N. 4. P. 735–737.

Bahmer T., Watz H., Develaska M. et al. Physical activity and fatigue in patients with sarcoidosis // Respiration. 2018. Vol. 95. N. 1. P. 18–26. DOI: https://doi.org/10.1159/000481827.

Balasubramanian A., Wade S.W., Adler R.A. et al. Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions // J. Bone. Miner. Res. 2018. Vol. 33. N. 10. P. 1881–1888. DOI: https://doi.org/10.1002/jbmr.3523.

Ballul T., Borie R., Crestani B. et al. Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs // Int. J. Cardiol. 2019. Vol. 276. P. 208–211. DOI: https://doi.org/10.1016/j.ijcard.2018.11.131.

Baltzan M., Mehta S., Kirkham T.H., Cosio M.G. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis // Am. J. Respir. Crit. Care Med. 1999. Vol. 160. N. 1. P. 192–197.

Bargagli E, Prasse A. Sarcoidosis: a review for the internist // Intern. Emerg. Med. 2018. Vol. 13. N. 3. P. 325–331.

Baughman R., Drent M., Judson M. et al. Sarcoidosis Treatment Guidelines. URL: https://stopsarcoidosis.org/wp-content/uploads/2013/03/FSR-Physicians-Protocol1.pdf (дата обращения: 06.02.2014).

Baughman R.P., Culver D.A., Judson M.A. A concise review of pulmonary sarcoidosis // Am. J. Respir. Crit. Care Med. 2011. Vol. 183. N. 5. P. 573–581.

Baughman R.P., Field S., Costabel U. et al. Sarcoidosis in America. Analysis based on health care use // Ann. Am. Thorac. Soc. 2016. Vol. 13. N. 8. P. 1244–1252.

Baughman R.P., Lower E.E. Leflunomide for chronic sarcoidosis // Sarcoidosis Vasc. Diffuse Lung Dis. 2004. Vol. 21. N. 1. P. 43–48.

Baughman R.P., Nunes H., Sweiss N.J. et al. Established and experimental medical therapy of pulmonary sarcoidosis // Eur. Respir. J. 2013. Vol. 41. N. 6. P. 1424–1438.

Baughman R.P., Winget D.B., Lower E.E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial // Sarcoidosis Vasc. Diffuse Lung Dis. 2000. Vol. 17. N. 1. P. 60–66.

Bechman K., Christidis D., Walsh S. et al. A review of the musculoskeletal manifestations of sarcoidosis // Rheumatology (Oxford). 2018. Vol. 57. N. 5. P. 777–783. DOI: https://doi.org/10.1093/rheumatology/kex317.

Besnard V., Calender A., Bouvry D. et al. G908R NOD2 variant in a family with sarcoidosis // Respir. Res. 2018. Vol. 19. N. 1. P. 44. DOI: https://doi.org/10.1186/s12931-018-0748-5.

Block N.L., Kava B.R. Genitourinary sarcoidosis: an essential review for the practicing clinician // Indian J. Urol. 2017. Vol. 33. N. 1. P. 6–12. DOI: https://doi.org/10.4103/0970-1591.195724.

Bohelay G., Bouaziz J.D., Nunes H. et al. Striking leflunomide efficacy against refractory cutaneous sarcoidosis // J. Am. Acad. Dermatol. 2014. Vol. 70. N. 5. P. e111–e113. DOI: https://doi.org/10.1016/j.jaad.2013.10.048.

Brie D., Sahebkar A., Penson P.E. et al.; Lipid, Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Effects of pentoxifylline on inflammatory markers and blood pressure: a systematic review and meta-analysis of randomized controlled trials // J. Hypertens. 2016. Vol. 34. N. 12. P. 2318–2329.

Chapman M.N., Fujita A., Sung E.K. et al. Sarcoidosis in the head and neck: an illustrative review of clinical presentations and imaging findings // AJR Am. J. Roentgenol. 2017. Vol. 208. N. 1. P. 66–75. DOI: https://doi.org/10.2214/AJR.16.16058.

Cremers J.P., Drent M., Bast A. et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide // Curr. Opin. Pulm. Med. 2013. Vol. 19. N. 5. P. 545–561.

De Vries J., Michielsen H., Van Heck G.L., Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS) // Br. J. Health Psychol. 2004. Vol. 9. P. 279–291.

Deverrière G., Flamans-Klein A., Firmin D. et al. Early onset pediatric sarcoidosis, diagnostic problems // Arch. Pediatr. 2012. Vol. 19. N. 7. P. 707–710. DOI: https://doi.org/10.1016/j.arcped.2012.04.024.

Dinsen S., Baslund B., Klose M. et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself // Eur. J. Intern. Med. 2013. Vol. 24. N. 8. P. 714–720. DOI: https://doi.org/10.1016/j.ejim.2013.05.014.

Drent M., Cremers J.P., Jansen T.L., Baughman R.P. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis // Sarcoidosis Vasc. Diffuse Lung Dis. 2014. Vol. 31. N. 2. P. 91–107.

Dubaniewicz A. “Danger theory” as a common mechanism of sarcoidosis induction by infectious and non-infectious factors — a role of environmental factors and autoimmunity // Pol. Merkur. Lekarski. 2018. Vol. 44. N. 261. P. 97–100.

Dubrey S., Sharma R., Underwood R. et al. Sarcoidosis of the cardio-pulmonary systems // Clin. Med. (Lond.). 2016. Vol. 16. N. 1. P. 34–41. DOI: https://doi.org/10.7861/clinmedicine.16-1-34.

Duong H., Bonham C.A. Sarcoidosis-associated pulmonary hypertension: pathophysiology, diagnosis, and treatment // Clin. Pulm. Med. 2018. Vol. 25. N. 2. P. 52–60. DOI: https://doi.org/10.1097/CPM.0000000000000252.

El Sayed F., Torbey G., Youssef H., Chababi M. Childhood sarcoidosis: diagnostic issues // Dermatol. Online J. 2013. Vol. 19. N. 10. Article ID 20037.

Esteves T., Aparicio G., Garcia-Patos V. Is there any association between Sarcoidosis and infectious agents? A systematic review and meta-analysis // BMC Pulm. Med. 2016. Vol. 16. N. 1. P. 165. DOI: https://doi.org/10.1186/s12890-016-0332.

Fretzayas A., Moustaki M., Vougiouka O. The puzzling clinical spectrum and course of juvenile sarcoidosis // World J. Pediatr. 2011. Vol. 7. N. 2. P. 103–110.

Garcia Ródenas M.D.M., Gayá Garcia-Manso I., Garcia Sevila R. Sarcoidosis associated with Interferon beta treatment // Med. Clin. (Barc.). 2019. Vol. 153. N. 5. P. e21–e22. DOI: https://doi.org/10.1016/j.medcli.2018.11.021.

Gavrysyuk V., Merenkova E., Gumeniuk G. et al. Effectiveness and safety of methotrexate monotherapy in patients with pulmonary sarcoidosis // Georgian Med. News. 2018. Vol. 283. P. 34–38.

Ghrenassia E., Mekinian A., Chapelon-Albric C. et al. Digestive-tract sarcoidosis: French nationwide case-control study of 25 cases // Medicine (Baltimore). 2016. Vol. 95. N. 29. Article ID e4279.

Grunewald J. Genetics of sarcoidosis // Curr. Opin. Pulm. Med. 2008. Vol. 14. N. 5. P. 434–439.

Hamzeh N., Voelker A., Forssen A. et al. Efficacy of mycophenolate mofetil in sarcoidosis // Respir. Med. 2014. Vol. 108. P. 1663–1669.

Hetzel J., Maldonado F., Ravaglia C. et al. Transbronchial cryobiopsies for the diagnosis of diffuse parenchymal lung diseases: expert statement from the Cryobiopsy Working Group on Safety and Utility and a call for standardization of the procedure // Respiration. 2018. Vol. 95. N. 3. P. 188–200. DOI: https://doi.org/10.1159/000484055.

Hoffman A.L., Milman N., Byg K.E. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children // Acta Paediatr. 2004. Vol. 93. P. 30–36.

Hu Y., Yibrehu B., Zabini D., Kuebler W.M. Animal models of sarcoidosis // Cell Tissue Res. 2017. Vol. 367. N. 3. P. 651–661. DOI: https://doi.org/10.1007/s00441-016-2526-3.

Ibitoye R.T., Wilkins A., Scolding N.J. Neurosarcoidosis: a clinical approach to diagnosis and management // J. Neurol. 2017. Vol. 264. N. 5. P. 1023–1028. DOI: https://doi.org/10.1007/s00415-016-8336-4.

James D.G., Jones Williams W. (eds). Sarcoidosis and Other Granulomatous Disorders. Philadelphia: Saunders, 1985. P. 163–166.

James W.E., Baughman R. Treatment of sarcoidosis: grading the evidence // Expert Rev. Clin. Pharmacol. 2018. Vol. 11. N. 7. P. 677–687. DOI: https://doi.org/10.1080/17512433.2018.1486706.

Johannson K.A., Marcoux V.S., Ronksley P.E., Ryerson C.J. Diagnostic yield and complications of transbronchial lung cryobiopsy for interstitial lung disease. A systematic review and meta-analysis // Ann. Am. Thorac. Soc. 2016. Vol. 13. N. 10. P. 1828–1838.

Jouni H., Chareonthaitawee P. Unraveling inflammation and oxidative stress in cardiac sarcoidosis // Circ. Cardiovasc. Imaging. 2017. Vol. 10. N. 12. Article ID e007287. DOI: https://doi.org/10.1161/CIRCIMAGING.117.007287.

Judson M.A. The clinical features of sarcoidosis: a comprehensive review // Clin. Rev. Allergy Immunol. 2015. Vol. 49. N. 1. P. 63–78. DOI: https://doi.org/10.1007/s12016-014-8450-y.

Judson M.A., Baughman R.P., Costabel U. et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis // Eur. Respir. J. 2014. Vol. 44. P. 1296–1307.

Jung J.H., Kim J.H., Song G.G. Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept // Z. Rheumatol. 2017. Vol. 76. N. 4. P. 372–374. DOI: https://doi.org/10.1007/s00393-016-0262-4.

Katta R., Nelson B., Chen D., Roenigk H. Sarcoidosis of the scalp: a case series and review of the literature // J. Am. Acad. Dermatol. 2000. Vol. 42. P. 690–692.

Kiedrowicz M., Kacalak-Rzepka A., Bielecka-Grzela S., Maleszka R. Antimalarial drugs in contemporary dermatologic therapy // Ann. Acad. Med. Stetin. 2011. Vol. 57. N. 1. P. 38–44.

Kikuchi N., Nunoda S., Serizawa N. et al. Combination therapy with corticosteroid and mycophenolate mofetil in a case of refractory cardiac sarcoidosis // J. Cardiol. Cases. 2016. Vol. 13. N. 4. P. 125–128. DOI: https://doi.org/10.1016/j.jccase.2015.12.008.

Kim T.K., Kang S.H., Moon H.S. et al. Pulmonary sarcoidosis that developed during the treatment of a patient with Crohn disease by using infliximab // Ann. Coloproctol. 2017. Vol. 33. N. 2. P. 74–77. DOI: https://doi.org/10.3393/ac.2017.33.2.74.